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We used unbiased metagenomic next-generation sequenc-
ing to diagnose a fatal case of meningoencephalitis caused 
by St. Louis encephalitis virus in a patient from California in 
September 2016. This case is associated with the recent 
2015–2016 reemergence of this virus in the southwestern 
United States.
St. Louis encephalitis virus (SLEV), in the Flaviviridae family, is an infectious RNA virus transmitted by Culex 
spp. mosquitoes (1,2). Clinical manifestations range from 
mild febrile illness to fatal neurologic disease. According 
to recent reports (3,4), SLEV reemerged in the summer of 
2015 in California and Arizona, USA, after a documented 
11-year absence of activity in California.
In June 2016, we launched a multi-institutional clini-
cal study titled Precision Diagnosis of Acute Infectious 
Diseases (PDAID). This 1-year study aimed to enroll 300 
patients to evaluate the clinical utility of a metagenomic 
next-generation sequencing (mNGS) assay for diagnosing 
infectious causes of meningitis and encephalitis from pa-
tient cerebrospinal fluid (CSF) samples (5,6). The mNGS 
assay uses an unbiased sequencing approach to compre-
hensively identify pathogens (viruses, bacteria, fungi, and 
parasites) in clinical samples (7). We report a fatal human 
case of SLEV infection diagnosed by mNGS in a PDAID 
study patient from California.
The Case
The case-patient was a 68-year-old man with a history of 
coronary artery disease, hypertension, and mantle cell lym-
phoma treated with 4 cycles of chemotherapy and granu-
locyte colony stimulating factor. He sought medical care 
at the end of August 2016 having had 2 days of fever (up 
to 39.4°C), chills, lethargy, and confusion. He had fallen 
twice because of dizziness and reported shortness of breath, 
cough, and new-onset urinary incontinence.
The patient was a retired oil-field worker living with 
his wife in Bakersfield, Kern County, California. He owned 
1 dog and had frequent contact with his 10 grandchildren. 
His travel history was notable for a trip to “the mountains” 
in late April 2016 (Payson, Arizona, elevation 1,500 m).
The patient was admitted to the hospital in early Septem-
ber 2016. An initial workup, including magnetic resonance 
imaging of the brain, was unrevealing. Empirical therapy 
with vancomycin, meropenem, and levofloxacin was started 
after lung imaging revealed inflammatory pneumonitis. On 
hospitalization day 3, the patient became acutely hypoxic 
with worsening altered mental status (AMS), and he was in-
tubated and transferred to the intensive care unit. A lumbar 
puncture revealed CSF pleocytosis (18 leukocytes/mm3; 35% 
monocytes, 33% lymphocytes, and 32% neutrophils); glu-
cose and protein were within reference ranges. Empiric an-
tibiotic therapy was continued, and acyclovir and antifungal 
therapy were added to his regimen. Repeat lumbar puncture 
performed on hospital day 9 showed persistent pleocytosis. 
All microbiologic test results for CSF, blood, and bronchoal-
veolar lavage were negative (Table 1), as was a workup for 
noninfectious causes (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/23/10/16-1986-Techapp1.pdf).
After enrolling the patient in the PDAID study, we 
analyzed CSF from hospitalization day 9 by mNGS test-
ing at University of California, San Francisco (online 
Technical Appendix) (8). RNA and DNA sequencing 
libraries from CSF yielded 8,056,471 and 9,083,963 se-
quence reads, respectively. In the RNA library, 236,615 
(2.9%) of the reads were identified as SLEV by using the 
SURPI+ (sequence-based ultra-rapid pathogen identifica-
tion) computational pipeline (7), with recovery of 99.4% 
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Table 1. Microbiologic testing results for a patient with fatal mosquito-borne St. Louis encephalitis virus infection diagnosed by 
metagenomic sequencing, California, 2016* 
Test Hospitalization day sample collected Result 
Serum studies 
 Bacterial cultures 0, 2, 4, 7 Negative 
 Fungal cultures 0, 2, 4, 7 Negative 
 Mycobacterial culture 10 Negative 
 Aspergillus antigen EIA 5 Negative 
 Adenovirus PCR 19 Negative 
 CMV DNA quantitative PCR 4, 12 Negative 
 EBV DNA quantitative PCR 10 Negative 
 Enterovirus RNA 19 Negative 
 HSV-1 and HSV-2 PCR 12 Negative 
 HHV-6 PCR 19 Negative 
 HIV RNA quantitative PCR 5 Negative 
 HBV DNA quantitative PCR 9 Negative 
 Leptospira DNA 14 Negative 
 Parvovirus B19 DNA 19 Negative 
 VZV DNA, qualitative PCR 19 Negative 
 Cryptococcal antigen 5 Negative 
CSF studies 
 HSV 1 and 2 PCR 3 Negative 
 Fungal culture 3 Negative 
 Bacterial culture 3  
 Coccidioides Ab CF, ID 8 Negative 
 CMV PCR 9  
 EBV PCR 3, 9 Negative 
 HHV-6 PCR 3 Negative 
 JC polyomavirus DNA, PCR 9 Negative 
 Mycobacterial culture 9 Negative 
 Mycobacterium tuberculosis DNA PCR 10 Negative 
 Meningoencephalitis antibody panel† 10 Negative 
 VDRL 9 Negative 
 VZV Ab IgG 9 Negative 
 West Nile virus RNA 9 Negative 
 mNGS for pathogen detection 9 SLEV 
Respiratory secretion testing‡ 
 Bacterial culture 4, 5, 8 Candida albicans 
 Fungal culture 5, 8 C. albicans 
 Respiratory virus panel§ 4 (NP swab), 5 Negative 
 Mycoplasma pneumoniae PCR 5  
 HSV-1 and HSV-2 PCR 5 Negative 
 CMV PCR 5 Negative 
 Pneumocystis DFA 5 Negative 
 Mycobacterial culture 5 Negative 
 Legionella culture and urinary Ag 5 Negative 
 Nocardia culture 8 Negative 
Serologic testing 
 Coccidioides IgG/IgM 4, 9 Negative 
 Coccidioides complement fixation 8 Negative 
 HCV Ab 9 Negative 
 HBV, core Ab and hepatitis B e Ab 9 Negative 
 Mycobacterium tuberculosis quantiferon gold 8 Negative 
 Q fever antibody 8 Negative 
 Rapid plasma reagin 10 Negative 
*Ab, antibody; Ag, antigen; BAL, bronchoalveolar lavage; CF, complement fixation; CMV, cytomegalovirus; DFA, direct fluorescent antigen; DNA, 
deoxyribonucleic acid; EBV, Epstein-Barr virus; EIA, enzyme immunoassay; HBV, hepatitis B virus; HCV, hepatitis C virus; HHV-6, human herpesvirus 6; 
HIV, human immunodeficiency virus, HSV, herpes simplex virus; ID, immunodiffusion; IFA, indirect fluroescent antibody; mNGS, metagenomic next-
generation sequencing; NP, nasopharyngeal; RNA, ribonucleic acid; SLEV, St. Louis encephalitis virus; VRDL, Venereal Disease Research Laboratory; 
VZV, varicella zoster virus. 
†Includes IgM and IgG testing for West Nile virus; California encephalitis virus; Eastern equine encephalitis virus; St. Louis encephalitis virus; Western 
equine encephalitis virus; lymphocytic choriomeningitis virus; herpes simplex virus types 1 and 2 (HSV-1 and 2); adenovirus; influenza A; influenza B; 
measles (IFA); mumps (IFA); varicella-zoster Ab CF; coxsackie A types 2, 4, 7, 9, 10, and 16; coxsackie B types 1, 2, 3, 4, 5, and 6; echovirus types 4, 7, 
9, 11, and 30; and CMV.  
‡Testing performed on bronchoalveolar lavage unless noted otherwise. 
§Detects the following viruses: influenza A; influenza A H1 seasonal; influenza A H3 seasonal; influenza A 2009 H1N1; influenza B; respiratory syncytial 
virus A and B; parainfluenza viruses 1–4; human metapneumovirus; human rhinovirus; adenovirus serogroups C and B/E; coronaviruses NL63, HKU1, 
229E, and OC43. 
 
DISPATCHES
of the predicted 10,936-bp virus genome. Subsequent 
mNGS testing of the patient’s CSF from hospitalization 
day 3 also was positive for SLEV.
The patient’s SLEV genome sequence was >99% 
identical with previously sequenced 2014–2015 SLEV 
isolates from mosquitoes in California and Arizona (4). 
Phylogenetic analysis placed the patient’s strain in a clus-
ter containing these isolates and viruses sequenced from 
mosquitoes in Argentina in 1978 and 2005 (9) (Figure). 
The patient’s SLEV was genetically distinct from the 2003 
Imperial Valley strain that had been circulating in Califor-
nia before an 11-year absence (12), suggesting that he was 
infected by the 2015–2016 reemergent genotype currently 
circulating in the southwestern United States (3,4). Further-
more, the patient’s SLEV genome was closely related to a 
strain sequenced from a mosquito pool collected in June 
2016 from Kern County (Figure, panel A), with 99.9% 
pairwise nucleotide identity and only 5 single-nucleotide 
variants across the genome.
After extensive discussion with his wife regarding the 
patient’s SLEV diagnosis and poor prognosis, the patient 
was transitioned to comfort care on hospitalization day 
23 and died the following day. Autopsy revealed residual 
mantle cell lymphoma and bronchopneumonia consistent 
with infection or chemical pneumonitis from aspiration. 
The diagnosis of SLEV meningoencephalitis was subse-
quently confirmed by positive reverse transcription PCR 
and virus culture testing from multiple laboratories (Table 
2). However, follow-up testing for SLEV from the patient’s 
CSF and serum was negative.
Conclusions
We present a case of SLEV infection in an elderly immu-
nocompromised patient hospitalized with fever and AMS 
1696 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 10, October 2017
Figure. Phylogeny and spread of St. Louis encephalitis virus. A) Multiple sequence alignment of 32 complete SLEV genomes from 
GenBank and the 2 SLEV genomes corresponding to the case-patient’s strain and a strain from a mosquito collected in June 2016 from 
Kern County, California (red circles and text). Alignment was performed using MAFFT (10), followed by tree generation using a neighbor-
joining algorithm using Geneious (11). The cluster containing the 2014–2016 California and Arizona SLEV genome, including those from 
the case-patient and 2016 mosquito pool, is rooted by SLEV strains sequenced from mosquitoes collected in Argentina in 1978 and 
2005 (black circles). Isolates are named by location, year of collection, strain name, and GenBank accession number. Bootstrap support 
values are given for each node. Scale bar indicates nucleotide substitutions per site. B) Geographic spread of SLEV in the Americas, 
from Argentina in 2005 to California and Arizona during 2014–2016. Because genome sequences from US states reporting SLEV activity 
are not publicly available and surveillance for SLEV in South and Central America is not routinely performed, the pathway or pathways 
by which the virus came to the southwestern United States remain unclear (question mark). SLEV, St. Louis encephalitis virus.
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and who experienced critical respiratory failure. Most 
SLEV infections are asymptomatic; when infections are 
symptomatic, clinical features include fever, lethargy, and 
confusion (1), with potential complications including sep-
sis, gastrointestinal hemorrhage, pulmonary embolism, and 
bronchopneumonia. In hindsight, SLEV infection is con-
sistent with the patient’s clinical presentation, with pneu-
monitis and respiratory decompensation possibly resulting 
from aspiration during the patient’s AMS from viral me-
ningoencephalitis. Deaths from SLEV infection during the 
first 2 weeks are generally from encephalitis, whereas later 
deaths are more often caused by complications of hospital-
ization, such as this patient’s bronchopneumonia.
Routine diagnosis of SLEV is challenging because se-
rologic testing is only performed by specialized reference 
laboratories, the period of viremia is brief, and molecular 
testing by reverse transcription PCR is not widely used. Cli-
nicians in California might fail to consider SLEV when ex-
amining a patient with nonspecific febrile illness, especially 
given the lack of virus or disease activity in the state during 
2004–2015. Antibody testing can be complicated by the ab-
sence of seroreactivity in elderly and immunocompromised 
patients, as observed in the case of this patient (Table 1), as 
well as potential cross-reactivity with other flavivirus infec-
tions, such as dengue, Zika virus, and West Nile virus (3).
The identification of SLEV infection in CSF by using 
a panpathogen metagenomic sequencing assay is another 
demonstration of the power of an unbiased approach to in-
fectious disease testing (5–7), although challenges remain 
with respect to test availability, interpretation, and valida-
tion (8). No antiviral therapy for SLEV has been proven to 
be efficacious, although interferon-α has been tried (13). 
With a laboratory sample-to-reporting time of 4 days, earlier 
sample submission might have spared our patient from the 
side effects of antimicrobial drug therapy, costly laboratory 
testing, and invasive procedures. Importantly, the family 
obtained reassurance and closure from communication of 
an established diagnosis.
During summer 2016, SLEV was reported in mosqui-
toes from 7 counties in California, including Kern County, 
where the patient resided (4). According to his wife, the 
patient often sat outdoors during the few weeks before hos-
pitalization, although she did not recall his reporting any 
mosquito bites. Nevertheless, we believe he most likely 
contracted SLEV in California, because his history of trav-
el to Arizona 5 months prior was not consistent with the 
incubation period of the disease (4–21 days); mosquitoes 
are less prevalent at the higher altitudes of Payson, Ari-
zona; and the patient’s SLEV sequence was most closely 
related to a strain from a June 2016 Kern County mosquito 
pool. Given the reemergence of SLEV in the southwestern 
United States, clinicians from affected areas will need to 
maintain a high index of suspicion for this disease, particu-
larly during local community outbreaks or high SLEV ac-
tivity detected through mosquito surveillance efforts.
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Table 2. Results of follow-up confirmatory testing for SLEV after mNGS result for a patient with fatal mosquito-borne St. Louis 
encephalitis virus infection diagnosed by metagenomic sequencing, California, 2016* 
Test (hospital day sample collected) Laboratory Result 
CSF studies 
 SLEV, RT-PCR (9) UCSF research lab Positive 
 SLEV, RT-PCR (3,9) CDPH Positive 
 SLEV, RT-PCR (3,9) CDC Positive 
 Viral culture (3,9) CDC Positive, confirmed as SLEV by RT-PCR 
 SLEV, IgG/IgM antibody (3,9) Quest Diagnostics Negative, <1:10 
 SLEV, PRNT for neutralizing antibodies (9) CDPH Negative, <1:10 
 WNV, IgM   
 WNV, PRNT for neutralizing antibodies (9) CDPH Negative, <1:10 
Serum studies   
 SLEV, RT-PCR (23) CDPH Negative 
 SLEV, IgM antibody (23) CDPH Negative, <1:10 
 WNV, IgM antibody (23) CDPH Negative, <1:10 
 SLEV, PRNT for neutralizing antibodies (23) CDPH Negative, <1:10 
 WNV, PRNT for neutralizing antibodies (23) CDPH Borderline positive, 1:10 (normal <1:10) 
*Tests were performed after mNGS testing of patient CSF was positive from aliquots collected on hospital days 3 and 9. CDC, Centers for Disease 
Control and Prevention; CDPH, California Department of Public Health; CSF, cerebrospinal fluid; mNGS, metagenomic next-generation sequencing; 
PRNT, plaque-reduction neutralization testing; RT-PCR, reverse transcription PCR; SLEV, St. Louis encephalitis virus; UCSF, University of California, 
San Francisco; WNV, West Nile virus. 
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